SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

Начало・Списък с акции・BioMerieux

Search

BioMerieux

Затворен

СекторЗдравеопазване

70.08 -1.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

69.4

Максимум

70.98

Ключови измерители
By Trading Economics
Приходи	75M 236M
Продажби	-18M 2B
P/E Средно за сектора	21.347 67.147
EPS	1.986
Дивидентна доходност	1.38
Марж на печалбата	11.663
Служители	14,562
EBITDA	200K 476M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+34.97% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.38% 2.36%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.8B 8.4B
Предишно отваряне	71.69
Предишно затваряне	70.08

Настроения в новините

By Acuity

54%

46%

291 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

113.1 / 118.6 Подкрепа & съпротива

BioMerieux Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 22:17 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4.05.2026 г., 23:47 ч. UTC

Печалби

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4.05.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Steady Amid Likely Technical Recovery -- Market Talk

4.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Regis: Jim Beyer To Be Chief Executive of Combined Company

4.05.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Shareholders to Own About 51% of Combined Company

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Board Unanimously Endorsed, Supported Deal

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Deal Unanimously Recommended by Vault Board

4.05.2026 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources to Acquire All Ordinary Shares in Vault

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources, Vault Minerals Agree to Merger of Equals

4.05.2026 г., 22:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4.05.2026 г., 22:26 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4.05.2026 г., 22:02 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4.05.2026 г., 22:00 ч. UTC

Пазарно говорене

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4.05.2026 г., 21:52 ч. UTC

Печалби

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Some Sectors More Affected Than Others>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4.05.2026 г., 21:49 ч. UTC

Печалби

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4.05.2026 г., 21:43 ч. UTC

Печалби

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4.05.2026 г., 21:41 ч. UTC

Печалби

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4.05.2026 г., 21:40 ч. UTC

Печалби

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Сравнение с други в отрасъла

Ценова промяна

BioMerieux Прогноза

Ценова цел

By TipRanks

34.97% нагоре

12-месечна прогноза

Среден 96.77 EUR 34.97%

Висок 138 EUR

Нисък 71.6 EUR

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за BioMerieux през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

1

Купи

5

Задържане

0

Продай

Според 6 анализатори, дали борсови рейтинги на BioMerieux през последните 3 месеца.

Техническа оценка

By Trading Central

113.1 / 118.6Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

291 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Други акции от сектора

SAN

Sanofi SA

74.115

SRT3

Sartorius AG

223.85

ORNBV.FI

Orion Oyj (Class B)

68.5

Live chat